Trial Profile
Study of Talimogene Laherparepvec Administered Endoscopically for the Treatment of Locally Advanced or Metastatic Pancreas Cancer Refractory to at Least One Chemotherapy Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 29 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 02 Aug 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2022.
- 31 Mar 2022 Status changed from recruiting to active, no longer recruiting.